Lv1
5 积分 2021-11-18 加入
Therapeutic opportunities for the treatment of NASH with genetically validated targets
7天前
已完结
Mitochondrial amidoxime‐reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome
8天前
已完结
mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes
8天前
已完结
Hepatocyte mARC1 promotes fatty liver disease
8天前
已完结
Therapeutic opportunities for the treatment of NASH with genetically validated targets
8天前
已完结
siRNA-mediated gene silencing for non-alcoholic fatty liver disease: A comprehensive review of molecular targets
8天前
已完结
NAFLD and NASH: etiology, targets and emerging therapies
12天前
已完结
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
12天前
已完结
Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis
12天前
已完结
Current therapies and new developments in NASH
18天前
已完结
皖公网安备34019202002308
